OKYO Pharma Limited (OKYO), a clinical-stage biopharmaceutical company, on Wednesday announced the initiation of its Phase 2a clinical trial for OK-101, a novel non-opioid therapeutic candidate aimed at treating neuropathic corneal pain or NCP.
The company anticipates completing enrollment of 48 patients by the end of the second quarter of 2025, with top-line data expected in the fourth quarter of 2025.
The trial is designed to evaluate the safety, efficacy, and tolerability of OK-101 in patients with NCP, a severe ocular condition for which no FDA-approved therapies currently exist.
OK-101 works by targeting corneal nerve damage, a key cause of the debilitating pain associated with NCP.
The trial is being led by Dr. Pedram Hamrah of Tufts Medical Center, a recognized expert in NCP.
OKYO also highlighted its continued progress in the treatment of dry eye disease or DED, with positive results from the Phase 2b trial of OK-101 for DED, showing significant improvements in patient symptoms.
For the six months ending September 30, 2024, the company reported a total comprehensive loss of $3.1 million for the period, a decrease from the $8.5 million loss in the same period of 2023.
OKYO reported total assets of $2.8 million, up from $1.5 million as of March 31, 2024.
The company had cash on hand of $1.0 million as of September 30, 2024, post-period, OKYO secured an additional $1.8 million in funding.
The company is optimistic about the potential of OK-101 to provide long-term relief for patients with both NCP and DED and is working closely with the FDA regarding future clinical plans for OK-101 in DED.
Currently, OKYO is trading at $1.15 up by 11.52%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.